Botox cosmetic, Nuceiva(botulinum toxin type a)
Nuceiva (botulinum toxin type a) is a protein pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Botox, Daxxify, Dysport, Xeomin (discontinued: Botox)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Abobotulinumtoxina
Incobotulinumtoxina
Daxibotulinumtoxina
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Daxxify | daxibotulinumtoxinA-lanm | Revance Therapeutics | N-761127 RX | 2022-09-07 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| babybig | Biologic Licensing Application | 2024-12-05 |
| botox | Biologic Licensing Application | 2023-11-18 |
| botox cosmetic | Biologic Licensing Application | 2024-10-18 |
| botox facial serum | C200263 | 2024-10-28 |
| botox serum | C200263 | 2024-11-03 |
| botox stock solution | C200263 | 2024-11-03 |
| botulinum toxin solution anti-aging serum | C200263 | 2024-10-21 |
| daxxify | Biologic Licensing Application | 2024-01-24 |
| dysport | Biologic Licensing Application | 2024-10-24 |
| protoxin | unapproved drug other | 2016-11-10 |
Show 2 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| genetic skin diseases | — | D012873 | — |
| dystonia | — | D004421 | — |
| fissure in ano | — | D005401 | K60.2 |
| strabismus | — | D013285 | H50.2 |
| blepharospasm | — | D001764 | G24.5 |
| muscle rigidity | — | D009127 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1470 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | — | — | — | 1 | 9 | 1 | — | 11 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 5 | 1 | — | 6 |
| Dystonic disorders | D020821 | — | G24 | — | — | 2 | 2 | 1 | 5 |
| Dystonia | D004421 | — | — | — | — | 2 | 2 | 1 | 5 |
| Torticollis | D014103 | — | F45.8 | — | — | 1 | 2 | 1 | 4 |
| Sleep bruxism | D020186 | — | G47.63 | — | — | — | 1 | — | 1 |
| Bruxism | D002012 | — | F45.8 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral palsy | D002547 | — | G80 | — | 1 | 4 | — | — | 5 |
| Blepharospasm | D001764 | — | G24.5 | — | 1 | 2 | — | 2 | 5 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | 3 | — | — | 4 |
| Brain injuries | D001930 | — | S06.9 | — | 1 | 3 | — | — | 4 |
| Sialorrhea | D012798 | — | K11.7 | — | 1 | 2 | — | — | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 2 | — | — | 3 |
| Facies | D019066 | — | — | — | — | 2 | — | — | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | 1 | — | — | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 2 | — | — | 2 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 2 | — | — | — | 2 |
| Tremor | D014202 | — | R25.1 | — | 2 | — | — | — | 2 |
| Paresis | D010291 | — | — | — | 2 | — | — | — | 2 |
| Clubfoot | D003025 | — | Q66.0 | — | 1 | — | — | — | 1 |
| Equinus deformity | D004863 | — | — | — | 1 | — | — | — | 1 |
| Paraplegia | D010264 | — | G82.2 | — | 1 | — | — | — | 1 |
| Talipes | D000070558 | — | Q66.1 | — | 1 | — | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
| Snoring | D012913 | — | R06.83 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thoracic outlet syndrome | D013901 | EFO_0007507 | G54.0 | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemifacial spasm | D019569 | — | — | — | — | — | — | 1 | 1 |
| Spasm | D013035 | — | M62.83 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Botulinum toxin type a |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
|
| Classification | Neurotoxin |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297862 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Botox – Allergan
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Botox – Warner Chilcott
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Daxxify – Revance Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Botulinum toxin type a
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,624 documents
View more details
Safety
Black-box Warning
Black-box warning for: Botox, Botox cosmetic, Daxxify, Dysport, Xeomin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,438 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use